-
Product Insights
Net Present Value Model: Linzess/Constella
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Linzess/Constella Drug Details Linaclotide (Linzess, Constella,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – naldemedine tosylate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry naldemedine tosylate Drug Details Naldemedine tosylate (S-297995, Symproic) is an opioid antagonist. It is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – dolcanatide
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry dolcanatide Drug Details Dolcanatide (SP-333, SLXG-1039) is under development for the treatment of ulcerative...
-
Product Insights
Opioid-Induced Constipation (OIC) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis - motions critical to moving food through the intestines. Additionally, opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of Opioid-Induced Constipation...
-
Product Insights
Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Alcohol Addiction pipeline market research report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant...
-
Product Insights
Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms;...
-
Product Insights
Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2018" provides an overview of Opioid-Induced Constipation (OIC) clinical trials scenario. This report provides top line data relating to the clinical trials on Opioid-Induced Constipation (OIC). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
The Insurance Industry in Cambodia, Key Trends and Opportunities to 2022
This report provides detailed analysis of the market trends, drivers and challenges in the Cambodian insurance industry. It provides key performance indicators such as written premium and claims during the review period (2013-2017) and forecast period (2017-2022). The report also analyzes distribution channels operating in the segment, gives a comprehensive overview of the Cambodian economy and demographics, and provides detailed information on the competitive landscape in the country. The report brings together GlobalData’s research, modeling and analysis expertise, giving insurers...
-
Product Insights
Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H2, 2016" provides an overview of Opioid-Induced Constipation (OIC) clinical trials scenario. This report provides top line data relating to the clinical trials on Opioid-Induced Constipation (OIC). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...